单肺通气期间个体化围手术期开放肺通气策略(iPROVE-OLV):多中心随机对照临床试验
本研究为多中心随机对照试验,纳入1380例择期行开放或电视辅助胸腔镜手术且使用单肺通气的成人患者,比较围手术期个体化开放肺通气策略(iOLA)与标准肺保护性通气。
要点
- iOLA可降低单肺通气肺切除患者术后7天内严重肺部并发症风险。
- iOLA组严重肺部并发症发生率为6%,标准肺保护性通气组为15%。
- iOLA包括肺泡复张至40 cm H2O吸气末压、个体化PEEP滴定及术后经鼻高流量氧疗。
核心结论
- 在单肺通气下接受肺切除的患者中,iOLA与标准肺保护性通气相比可降低严重术后肺部并发症风险。
研究设计与样本
- 多中心、随机对照临床试验,在西班牙、意大利、土耳其、埃及和厄瓜多尔的25家医院进行。
- 2018年9月11日至2022年6月14日共纳入1380例成人患者(年龄≥18岁),最终分析1308例,iOLA组670例,标准肺保护性通气组638例。
- 随机分配比例为1:1,按中心分层,采用意向性分析。
主要发现
- 术后7天内严重肺部并发症复合结局发生率:iOLA组40例(6%),标准组97例(15%)。
- 复张操作相关不良事件报告5例。
关键数值与推荐
- iOLA方案包括肺泡复张至40 cm H2O吸气末压,随后以最佳呼吸系统顺应性滴定个体化PEEP,术后采用经鼻高流量氧疗个体化呼吸支持。
- 标准肺保护性通气组术中接受4 cm H2O PEEP联合术后常规氧疗。
- 主要结局为术后7天内严重肺部并发症复合结局,包括需支气管镜的肺不张、严重呼吸衰竭、对侧气胸、早期拔管失败、急性呼吸窘迫综合征、肺部感染、支气管胸膜瘘和脓胸。
临床怎么用
- 对行单肺通气肺切除的成人患者,可考虑采用iOLA策略以降低严重术后肺部并发症风险。
- iOLA实施包括术中肺泡复张至40 cm H2O、个体化PEEP滴定及术后经鼻高流量氧疗。
局限性
- 由于试验设置,手术室和术后病房常规监测数据未设盲。
- 术后24小时数据由对分组设盲的研究者采集。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It is uncertain whether individualisation of the perioperative open-lung approach (OLA) to ventilation reduces postoperative pulmonary complications in patients undergoing lung resection. We compared a perioperative individualised OLA (iOLA) ventilation strategy with standard lung-protective ventilation in patients undergoing thoracic surgery with one-lung ventilation. METHODS: This multicentre, randomised controlled trial enrolled patients scheduled for open or video-assisted thoracic surgery using one-lung ventilation in 25 participating hospitals in Spain, Italy, Turkey, Egypt, and Ecuador. Eligible adult patients (age ≥18 years) were randomly assigned to receive iOLA or standard lung-protective ventilation. Eligible patients (stratified by centre) were randomly assigned online by local principal investigators, with an allocation ratio of 1:1. Treatment with iOLA included an alveolar recruitment manoeuvre to 40 cm H2O of end-inspiratory pressure followed by individualised positive end-expiratory pressure (PEEP) titrated to best respiratory system compliance, and individualised postoperative respiratory support with high-flow oxygen therapy. Participants allocated to standard lung-protective ventilation received combined intraoperative 4 cm H2O of PEEP and postoperative conventional oxygen therapy. The primary outcome was a composite of severe postoperative pulmonary complications within the first 7 postoperative days, including atelectasis requiring bronchoscopy, severe respiratory failure, contralateral pneumothorax, early extubation failure (rescue with continuous positive airway pressure, non-invasive ventilation, invasive mechanical ventilation, or reintubation), acute respiratory distress syndrome, pulmonary infection, bronchopleural fistula, and pleural empyema. Due to trial setting, data obtained in the operating and postoperative rooms for routine monitoring were not blinded. At 24 h, data were acquired by an investigator blinded to group allocation. All analyses were performed on an intention-to-treat basis. This trial is registered with ClinicalTrials.gov, NCT03182062, and is complete. FINDINGS: Between Sept 11, 2018, and June 14, 2022, we enrolled 1380 patients, of whom 1308 eligible patients (670 [434 male, 233 female, and three with missing data] assigned to iOLA and 638 [395 male, 237 female, and six with missing data] to standard lung-protective ventilation) were included in the final analysis. The proportion of patients with the composite outcome of severe postoperative pulmonary complications within the first 7 postoperative days was lower in the iOLA group compared with the standard lung-protective ventilation group (40 [6%] vs 97 [15%], relative risk 0·39 [95% CI 0·28 to 0·56]), with an absolute risk difference of -9·23 (95% CI -12·55 to -5·92). Recruitment manoeuvre-related adverse events were reported in five patients. INTERPRETATION: Among patients subjected to lung resection under one-lung ventilation, iOLA was associated with a reduced risk of severe postoperative pulmonary complications when compared with conventional lung-protective ventilation. FUNDING: Instituto de Salud Carlos III and the European Regional Development Funds.
引用
- Ferrando C, Carramiñana A, Piñeiro P, et al. Individualised, perioperative open-lung ventilation strategy during one-lung ventilation (iPROVE-OLV): a multicentre, randomised, controlled clinical trial. Lancet Respir Med. 2023. PMID: 38065200. doi:10.1016/S2213-2600(23)00346-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。